{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T18:25:32Z","timestamp":1773339932345,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.vaccine.2021.02.045","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T16:56:10Z","timestamp":1614963370000},"page":"1826-1830","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Determination of serum neutralizing antibodies reveals important difference in quality of antibodies against pertussis toxin in children after infection"],"prefix":"10.1016","volume":"39","author":[{"given":"Yuxiao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yarong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoguai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaokang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiushui","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.vaccine.2021.02.045_b0005","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1021\/bi00265a021","article-title":"Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model","volume":"21","author":"Tamura","year":"1982","journal-title":"Biochemistry"},{"issue":"2","key":"10.1016\/j.vaccine.2021.02.045_b0010","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2217\/fmb.14.123","article-title":"Investigating pertussis toxin and its impact on vaccination","volume":"10","author":"Loic","year":"2015","journal-title":"Future Microbiol"},{"issue":"50","key":"10.1016\/j.vaccine.2021.02.045_b0015","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1016\/j.vaccine.2012.10.009","article-title":"Acellular pertussis vaccines in China","volume":"30","author":"Wang","year":"2012","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2021.02.045_b0020","doi-asserted-by":"crossref","first-page":"ftv050","DOI":"10.1093\/femspd\/ftv050","article-title":"Seroprevalence studies of pertussis: what have we learned from different immunized populations","volume":"73","author":"Barkoff","year":"2015","journal-title":"Pathog Dis"},{"key":"10.1016\/j.vaccine.2021.02.045_b0025","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.3389\/fimmu.2019.01344","article-title":"Pertussis Prevention: reasons for resurgence, and differences in the current acellular pertussis vaccines","volume":"10","author":"Esposito","year":"2019","journal-title":"Front Immunol"},{"issue":"20","key":"10.1016\/j.vaccine.2021.02.045_b0030","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0264-410X(98)00227-8","article-title":"Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis","volume":"16","author":"Storsaeter","year":"1998","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2021.02.045_b0035","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/S1473-3099(18)30646-7","article-title":"PERISCOPE: road towards effective control of pertussis","volume":"19","author":"Diavatopoulos","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2021.02.045_b0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0092-1157(85)80034-2","article-title":"The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells","volume":"13","author":"Gillenius","year":"1985","journal-title":"J Biol Stand"},{"issue":"7","key":"10.1016\/j.vaccine.2021.02.045_b0045","doi-asserted-by":"crossref","first-page":"e0181181","DOI":"10.1371\/journal.pone.0181181","article-title":"A high seroprevalence of antibodies to pertussis toxin among Japanese adults: qualitative and quantitative analyses","volume":"12","author":"Moriuchi","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2021.02.045_b0050","unstructured":"National Health Commission of the People\u2019s Republic of China. WS 274-2007 Diagnostic criteria for pertussis Available from: http:\/\/www.nhc.gov.cn\/wjw\/s9491\/201410\/52040bc16d3b4eecae56ec28b3358666.shtml [accessed December 2020]."},{"issue":"11","key":"10.1016\/j.vaccine.2021.02.045_b0055","doi-asserted-by":"crossref","first-page":"O825","DOI":"10.1111\/1469-0691.12671","article-title":"High prevalence of erythromycin-resistant Bordetella pertussis in Xi'an","volume":"20","author":"Wang","year":"2014","journal-title":"China Clin Microbiol Infect"},{"issue":"7","key":"10.1016\/j.vaccine.2021.02.045_b0060","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3390\/toxins11070417","article-title":"Assays for determining pertussis toxin activity in acellular pertussis vaccines","volume":"11","author":"Markey","year":"2019","journal-title":"Toxins (Basel)"},{"issue":"51","key":"10.1016\/j.vaccine.2021.02.045_b0065","doi-asserted-by":"crossref","first-page":"7160","DOI":"10.1016\/j.vaccine.2017.10.082","article-title":"Towards replacement of the a cellular pertussis vaccine safety test: comparison of in vitro cytotoxic activity and in vivo activity in mice","volume":"35","author":"Wagner","year":"2017","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2021.02.045_b0070","first-page":"51","article-title":"Collaborative study for the standardisation of the histamine sensitizing test in mice and the CHO cell-based assay for the residual toxicity testing of acellular pertussis vaccines","volume":"2010","author":"Xing","year":"2010","journal-title":"Pharmeur Bio Sci Notes"},{"issue":"8","key":"10.1016\/j.vaccine.2021.02.045_b0075","doi-asserted-by":"crossref","first-page":"e1161","DOI":"10.1002\/cti2.1161","article-title":"Differences in epitope-specific antibodies to pertussis toxin after infection and acellular vaccinations","volume":"9","author":"Knuutila","year":"2020","journal-title":"Clin Transl Immunology"},{"issue":"3","key":"10.1016\/j.vaccine.2021.02.045_b0080","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nri2508","article-title":"B-cell responses to vaccination at the extremes of age","volume":"9","author":"Siegrist","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2021.02.045_b0085","first-page":"1700","article-title":"Antibody response to respiratory syncytial virus infection in children <18 months old","volume":"12","author":"Esposito","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"10.1016\/j.vaccine.2021.02.045_b0090","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/infdis\/158.5.991","article-title":"Toxin-neutralizing antibodies in patients with pertussis, as determined by an assay using Chinese hamster ovary cells","volume":"158","author":"Trollfors","year":"1988","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2021.02.045_b0095","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1600-0463.2010.02664.x","article-title":"Pertussis serology: assessment of IgG anti-PT ELISA for replacement of the CHO cell assay","volume":"118","author":"Dalby","year":"2010","journal-title":"APMIS"},{"issue":"5","key":"10.1016\/j.vaccine.2021.02.045_b0100","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/infdis\/160.5.838","article-title":"Serum IgG, IgA, and IgM responses to pertussis toxin, filamentous hemagglutinin, and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine","volume":"160","author":"Thomas","year":"1989","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21002255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21002255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:53:52Z","timestamp":1759402432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21002255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":20,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0264410X21002255"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.045","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of serum neutralizing antibodies reveals important difference in quality of antibodies against pertussis toxin in children after infection","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.02.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}